COMMUNIQUÉS West-GlobeNewswire

-
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
01/09/2024 -
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
01/09/2024 -
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
01/09/2024 -
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
31/08/2024 -
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
31/08/2024 -
Avricore Grants Options
31/08/2024 -
Vision Sensing Acquisition Corp. Announces Intention to Extend the Period to Consummate Its Initial Business Combination to October 3, 2024
30/08/2024 -
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
30/08/2024 -
Jushi Holdings Inc. Announces Filing of Canadian Preliminary Base Shelf Prospectus
30/08/2024 -
Receipt of Nasdaq Delisting Determination - Plans to Appeal
30/08/2024 -
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update
30/08/2024 -
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30/08/2024 -
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
30/08/2024 -
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
30/08/2024 -
Fagron’s share buy-back program: Weekly update
30/08/2024 -
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
30/08/2024 -
Total number of shares and voting rights in Zealand Pharma on August 30, 2024
30/08/2024 -
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
30/08/2024 -
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
30/08/2024
Pages